Celldex Therapeutics, Inc. (CLDX)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

The chart shows the growth of an initial investment of $10,000 in Celldex Therapeutics, Inc., comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.

Celldex Therapeutics, Inc. (CLDX) has returned 16.79% so far this year and 74.77% over the past 12 months. Over the last ten years, CLDX has returned -6.06% per year, falling short of the S&P 500 Index benchmark, which averaged 12.16% annually.

Based on dividend-adjusted daily data since Mar 10, 2008, CLDX's average daily return is +0.10%, while the average monthly return is +2.83%. At this rate, your investment would double in approximately 2.1 years.

Historically, 49% of months were positive and 51% were negative. The best month was Jun 2020 with a return of +386.9%, while the worst month was Apr 2018 at -68.2%. The longest winning streak lasted 7 consecutive months, and the longest losing streak was 7 months.

On a daily basis, CLDX closed higher 47% of trading days. The best single day was Jun 11, 2020 with a return of +82.4%, while the worst single day was Apr 16, 2018 at -64.6%.

Celldex Therapeutics, Inc. has an annualized alpha of 10.17%, beta of 1.33, and R² of 0.11 versus S&P 500 Index. Calculated based on daily prices since March 11, 2008.

• This stock participated in 176.54% of S&P 500 Index downside but only 132.98% of its upside — more exposed to losses than it benefited from rallies.
• R² of 0.11 means this stock moves largely independently of S&P 500 Index — capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

CLDX ranks 78 for risk / return — better than 78% of stocks on our site. You're getting solid returns for the risk taken. A good sign, especially for investors who want growth without excessive volatility.

The table below present risk-adjusted performance metrics for Celldex Therapeutics, Inc. (CLDX) and compare them to a chosen benchmark (S&P 500 Index).

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the Celldex Therapeutics, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Celldex Therapeutics, Inc. was 99.73%, occurring on Mar 20, 2020. The portfolio has not yet recovered.

The current Celldex Therapeutics, Inc. drawdown is 94.41%.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of Celldex Therapeutics, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how Celldex Therapeutics, Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.